Skip to content

13F-HR filed by Euclidean Capital LLC

Euclidean Capital LLC filed this 13F-HR for the quarter ended 2022-06-30, filed 2022-08-15, with 10 holding rows worth $117,575,000.

Accession
0001012975-22-000358
Filed
2022-08-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2022

A holdings report, 10 entries on the cover page, a total value of $117,575,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $117,575,000 with VALUE read as thousands by filing date, 13F file number 028-20777. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
PMV PHARMACEUTICALS INC69353Y103COM2,336,909$33,301,000thousands by filing date
23ANDME HOLDING CO90138Q108CLASS A COM10,243,122$25,403,000thousands by filing date
FOGHORN THERAPEUTICS INC344174107COMMON STOCK1,261,261$17,153,000thousands by filing date
ALECTOR INC014442107COMMON STOCK980,894$9,966,000thousands by filing date
NGM BIOPHARMACEUTICALS INC62921N105COM746,674$9,572,000thousands by filing date
RAPT THERAPEUTICS INC75382E109COM432,900$7,900,000thousands by filing date
TENAYA THERAPEUTICS INC87990A106COM915,705$5,155,000thousands by filing date
1ST FINL BANCORP320209109COM173,576$3,367,000thousands by filing date
ORIC PHARMACEUTICALS INC68622P109COM747,550$3,349,000thousands by filing date
Surrozen, Inc.86889P109COM802,963$2,409,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-22-000358this filing2022-08-15acceptance time not in the bulk data set